Should I buy or sell Genelux stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNLX shares. View GNLX analyst ratings or view top-rated stocks .

What is Genelux's stock price target for 2024?

4 brokers have issued twelve-month target prices for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 291.5% from the stock's current price. View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts .

How have GNLX shares performed in 2024?

Genelux's stock was trading at $14.01 at the beginning of the year. Since then, GNLX stock has decreased by 36.2% and is now trading at $8.94. View the best growth stocks for 2024 here .

When is Genelux's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our GNLX earnings forecast .

How were Genelux's earnings last quarter?

Genelux Co. (NASDAQ:GNLX) posted its earnings results on Tuesday, November, 14th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.08.

When did Genelux IPO?

(GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets served as the underwriters for the IPO.

Who are Genelux's major shareholders?

Genelux's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Provident Wealth Management LLC (0.59%), Charles Schwab Investment Management Inc. (0.56%), LifeSteps Financial Inc. (0.13%), KWB Wealth (0.09%), San Luis Wealth Advisors LLC (0.09%) and UBS Group AG (0.08%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu. View institutional ownership trends .

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GNLX

Genelux (GNLX) Stock Price, News & Analysis

$8.94

-0.43 (-4.59%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $8.73
▼
$9.79
50-Day Range: $8.43
▼
$16.19
52-Week Range: $5.67
▼
$40.98

Volume: 155,100 shs
Average Volume: 104,139 shs
Market Capitalization: $238.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.00

Get Genelux alerts:

Genelux MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 291.5% Upside
$35.00 Price Target
Short Interest: Bearish
5.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: Selling Shares
$556,500 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.10) to ($0.88) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.55 out of 5 stars

Medical Sector

716th out of 922 stocks

Pharmaceutical Preparations Industry

343rd out of 429 stocks

3.5

Analyst's Opinion

Consensus Rating
Genelux has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.00, Genelux has a forecasted upside of 291.5% from its current price of $8.94.
Amount of Analyst Coverage
Genelux has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.50% of the float of Genelux has been sold short.
Short Interest Ratio / Days to Cover
Genelux has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in Genelux has recently increased by 2.86%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Genelux does not currently pay a dividend.
Dividend Growth
Genelux does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GNLX.

2.2

News and Social Media Coverage

News Sentiment
Genelux has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Genelux this week, compared to 1 article on an average week.
MarketBeat Follows
Only 4 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $556,500.00 in company stock.
Percentage Held by Insiders
11.70% of the stock of Genelux is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.77% of the stock of Genelux is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Genelux are expected to grow in the coming year, from ($1.10) to ($0.88) per share.

See Top Rated MarketRank™ Stocks Here

About Genelux Stock (NASDAQ:GNLX)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

GNLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNLX Stock News Headlines

February 6, 2024 | msn.com

Genelux Corp. Unveils Future-Oriented Corporate Presentation

February 3, 2024 | msn.com

Genelux Corp. Estimates $23.2 Million in Year-End Assets

February 12, 2024 | The Freeport Society (Ad)

Biden Out, _______ In?

A new poll shows that two-thirds of Democrats want Biden to drop out of the 2024 race. The truth will shock you.

January 23, 2024 | finance.yahoo.com

Healthcare IT Leaders Adds Health Industry Veteran Mary Mirabelli to Board of Directors

December 21, 2023 | benzinga.com

Genelux Stock (NASDAQ:GNLX) Dividends: History, Yield and Dates

December 15, 2023 | finance.yahoo.com

Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)

November 27, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Genelux (GNLX) with Buy Recommendation

November 27, 2023 | msn.com

Genelux gets fast track status for Olvi-Vec in ovarian cancer

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

November 27, 2023 | msn.com

HC Wainwright starts Genelux at buy, cites Olvi-Vec potential

November 27, 2023 | markets.businessinsider.com

Genelux Says FDA Grants Fast Track Designation For Olvi-Vec To Treat Ovarian Cancer

November 27, 2023 | finance.yahoo.com

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

November 23, 2023 | benzinga.com

Genelux VP Sold $191K In Company Stock

November 17, 2023 | finance.yahoo.com

Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%

November 15, 2023 | msn.com

Genelux GAAP EPS of -$0.20 misses by $0.02

November 14, 2023 | finance.yahoo.com

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

October 31, 2023 | morningstar.com

Genelux Corp GNLX

October 27, 2023 | msn.com

Genelux 10% owner Aladar Szalay discloses sale of 5,704 shares

October 27, 2023 | benzinga.com

10% Owner of Genelux Makes $110K Sale

October 26, 2023 | msn.com

Genelux Corporation 10% owner discloses sale of 49,987 shares

October 26, 2023 | benzinga.com

Genelux Insider Trades Send a Signal

October 26, 2023 | benzinga.com

VP at Genelux Exercises Options Worth $97K

October 11, 2023 | benzinga.com

Genelux 10% Owner Trades Company's Stock

October 6, 2023 | msn.com

Genelux (GNLX) Price Target Increased by 8.99% to 35.02

October 5, 2023 | benzinga.com

Genelux Recent Insider Activity

September 28, 2023 | benzinga.com

Genelux VP Acquires 5,200 Shares After Exercising Company Stock Options

September 28, 2023 | benzinga.com

Genelux 10% Owner Sold $1.03M In Company Stock

See More Headlines

Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 2/12/2024
Next Earnings (Estimated): 2/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GNLX
CUSIP: N/A
CIK: 1231457
Web: www.genelux.com
Phone: 805-267-9889
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.00
High Stock Price Target: $40.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +291.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,210,000.00
Net Margins: N/A
Pretax Margin: -10,514.71%
Return on Equity: -747.85%
Return on Assets: -115.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.56
Quick Ratio: 3.56

Sales & Book Value

Annual Sales: $11.07 million
Price / Sales: 21.58
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.51) per share
Price / Book: -5.92

Miscellaneous

Outstanding Shares: 26,720,000
Free Float: 23,592,000
Market Cap: $238.88 million
Optionable: Not Optionable
Beta: N/A

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Thomas Zindrick J.D. (Age 65)
Chairman, CEO & President
Comp: $500k
Mr. Sean Ryder J.D. (Age 55)
General Counsel & Corporate Secretary
Comp: $380k
Ms. Lourie S. Zak (Age 61)
CFO & Principal Accounting Officer
Dr. Joseph Cappello Ph.D. (Age 67)
Chief Technical Officer
Comp: $213.08k
Dr. Yong Yu Ph.D. (Age 53)
Senior Vice President of Clinical Development
Comp: $242.62k
Prof. Paul Scigalla M.D. (Age 78)
Ph.D., Chief Medical Officer
Ms. Caroline Jewett (Age 59)
VP & Head of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genelux stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNLX shares.
View GNLX analyst ratings or view top-rated stocks.
What is Genelux's stock price target for 2024?: 4 brokers have issued twelve-month target prices for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 291.5% from the stock's current price.
View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts.
How have GNLX shares performed in 2024?: Genelux's stock was trading at $14.01 at the beginning of the year. Since then, GNLX stock has decreased by 36.2% and is now trading at $8.94.
View the best growth stocks for 2024 here.
When is Genelux's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our GNLX earnings forecast.

How were Genelux's earnings last quarter?: Genelux Co. (NASDAQ:GNLX) posted its earnings results on Tuesday, November, 14th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.08.
When did Genelux IPO?: (GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets served as the underwriters for the IPO.
Who are Genelux's major shareholders?: Genelux's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Provident Wealth Management LLC (0.59%), Charles Schwab Investment Management Inc. (0.56%), LifeSteps Financial Inc. (0.13%), KWB Wealth (0.09%), San Luis Wealth Advisors LLC (0.09%) and UBS Group AG (0.08%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu.
View institutional ownership trends.
How do I buy shares of Genelux?: Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNLX) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genelux (GNLX) Stock Price, News & Analysis

Genelux MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Genelux Stock (NASDAQ:GNLX)

GNLX Stock Price History

GNLX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GNLX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™